Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tianjin Sets Up Pharmaceutical Innovation And Technology Transfer Center

This article was originally published in PharmAsia News

Executive Summary

Tianjin Institute of Pharmaceutical Research (TIPR), Tianjin Centre for Drug Safety Evaluation and Research, and TIPR Pharmaceutical Responsible Co. Ltd. will jointly set up a pharmaceutical innovation and technology transfer center at the Binhai Hi-Tech Park in Tianjin. The 370-million-yuan ($51.5 million) facility is expected to generate up to 1.5 billion yuan ($208.9 million) of production value for its programs within three years of operation. The center will raise Tianjing city's drug R&D and technical service levels by stimulating beneficial interaction between scientific research and industry. The integration of innovation and technology transfer will greatly spur the development of bioengineering and pharmaceutical industries in the area. (Click here for more - Chinese Language)

You may also be interested in...

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines

US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts